Physician profile
Christi Kidd
NPI 1275736092
$15,522.55
in general payments reported to CMS, 2019-2025
31 companies · $9,969 in 2025
The $9,969 reported for 2025 was more than what 99% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $980 · 2020: $43.29 · 2021: $342 · 2022: $272 · 2023: $195 · 2024: $3,721 · 2025: $9,969.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $13K · Food and Beverage: $685.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $13,200.00 |
| Food and Beverage | $685.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mimedx Group, INC. | $13,200.00 | 2024-2025 | Bovine Collagen |
| Intuitive Surgical, INC. | $856.01 | 2019 | |
| Astellas Pharma US INC | $205.77 | 2023-2025 | Veozah |
| Abbvie INC. | $195.99 | 2019-2023 | |
| Pfizer INC. | $182.21 | 2020-2024 | |
| Hologic Sales and Service, LLC | $141.95 | 2021-2025 | Aptima, Thinprep 2000 Processor |
| Mayne Pharma Commercial LLC | $117.74 | 2021-2024 | |
| Organon LLC | $95.36 | 2021-2025 | Nexplanon |
| Innovation Technologies INC | $58.39 | 2023-2024 | Irrisept |
| Minerva Surgical, INC | $44.61 | 2022 | |
| Myovant Sciences INC. | $41.20 | 2021 | |
| Sage Therapeutics, LLC | $39.65 | 2025 | Zurzuvae |
| Meditrina | $34.48 | 2021-2022 | |
| Exeltis, USA INC. | $30.04 | 2023 | Slynd |
| Medtronic, INC. | $27.90 | 2024 | Ligasure |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Millicent US INC | $27.09 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $20.08 | 2019 | |
| Becton, Dickinson and Company | $19.88 | 2021 | |
| Therapeuticsmd, INC. | $17.95 | 2019 | |
| Baxter Healthcare | $16.66 | 2020 | |
| Abbott Laboratories | $16.31 | 2024 | Proclaim |
| Kci USA, INC. | $15.70 | 2019 | |
| Aspira Women'S Health INC | $15.17 | 2022 | |
| Supernus Pharmaceuticals, INC. | $14.22 | 2025 | Qelbree |
| Ascend Therapeutics US, LLC | $13.47 | 2021 | |
| Smith+Nephew, INC. | $13.37 | 2022 | |
| Lupin INC. | $12.87 | 2019 | |
| Avanos Medical | $12.86 | 2020 | |
| Evofem Biosciences, INC. | $12.60 | 2022 | |
| Merck Sharp & Dohme LLC | $11.62 | 2019 | |
| Medicem INC. | $11.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christi Kidd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.